Kane Biotech's Biofilm-Busting Gel Shows Promise for Toughest Wounds

WINNIPEG, Manitoba – December 17, 2025 – New clinical data from Kane Biotech Inc. is providing a significant ray of hope for patients suffering from some of the most persistent and difficult-to-heal wounds. At the prestigious Innovations in Wound Healing (IWH) Annual Meeting held last week in Florida, the company presented compelling evidence that its advanced wound gel, revyve®, can successfully treat chronic wounds that have failed to respond to conventional therapies, including those resulting from radiation therapy and the debilitating skin disease Hidradenitis Suppurativa (HS).

The findings underscore a potential paradigm shift in a field grappling with the twin challenges of an aging population and rising antibiotic resistance. By targeting the underlying cause of many non-healing wounds—bacterial biofilms—Kane Biotech is positioning its technology as a critical tool for clinicians and a lifeline for patients who have endured years of pain and infection.

Confronting the Biofilm Barrier

At the heart of many non-healing wounds lies a formidable, invisible enemy: biofilm. These are not simply collections of bacteria, but highly organized, cooperative colonies encased in a slimy, protective matrix. According to extensive research, biofilms are present in at least 78% of all chronic wounds. This protective shield makes the embedded bacteria up to 1,000 times more resistant to standard antibiotics and the body’s own immune defenses.

This resistance is a primary reason why wounds stall, leading to a cycle of chronic inflammation, persistent infection, and tissue damage. The National Institutes of Health estimates that a staggering 80% of all human infections involve biofilms, making them a central villain in the global health crisis of antibiotic resistance.

Kane Biotech's revyve® Antimicrobial Wound Gel is engineered to dismantle this fortress. Its unique, triple-action formulation combines three key components:

• A powerful, broad-spectrum antimicrobial (PHMB): This agent effectively kills a wide range of bacteria without contributing to the development of antimicrobial resistance.
• Patented coactiv+® antibiofilm technology: This agent specifically targets and breaks down the protective biofilm matrix, exposing the bacteria within.
• A high-concentration surfactant: This component cleanses the wound bed, aids in the removal of dead tissue, and helps the other active ingredients penetrate deep into the wound.

By combining these elements, revyve® is designed not just to manage bacteria, but to fundamentally disrupt the biofilm structure that enables them to thrive, creating an optimal environment for the body to begin its natural healing process.

Breakthroughs in the Toughest Cases

The data presented at the IWH conference moves beyond general chronic wounds to highlight revyve®'s efficacy in patient populations with few viable treatment options. Two areas of focus were particularly noteworthy: chronic radiation-induced ulcers and Hidradenitis Suppurativa (HS).

Radiation therapy, a cornerstone of modern cancer treatment, can unfortunately cause severe collateral damage to healthy tissue. In some cases, this results in chronic, non-healing ulcers in the irradiated area, as the tissue's blood supply and regenerative capacity are permanently compromised. The new findings included a case study of a chronic radiation-induced Achilles ulcer—a wound in a notoriously difficult-to-heal location—that showed significant healing progress with revyve® gel. This suggests the technology can support recovery even in tissue severely compromised by radiation, where other treatments often fail.

Equally significant are the findings related to Hidradenitis Suppurativa. HS is a chronic, painful, and deeply distressing inflammatory skin disease characterized by recurrent abscesses, nodules, and tunneling wounds, typically in the armpits and groin. Affecting up to 1% of the U.S. population and with a diagnostic delay that can stretch over seven years, HS carries a heavy physical and psychological burden. Traditional treatments, including long-term antibiotics and biologics, have limitations and variable success rates. Kane's data illustrated revyve®'s potential to reduce the bacterial and biofilm burden in HS wounds, improving outcomes in a condition that leaves many patients feeling hopeless.

A Strategic Play in a Crowded Market

While the science is compelling, Kane Biotech is also navigating the fiercely competitive advanced wound care market, a sector valued at over $16 billion in 2025 and projected to grow substantially. Industry giants like Smith & Nephew and Convatec have their own biofilm-focused strategies and products, promoting concepts like "Biofilm Defense" and "Wound Hygiene."

However, Kane's focused approach on a triple-action formula and its demonstrated success in niche, high-need areas like HS and radiation ulcers could provide a key market differentiator. The recent data serves as critical validation that strengthens the company's position. Having already secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for both its revyve® gel and spray, as well as approval from Health Canada for the gel, the company has cleared major regulatory hurdles.

The presentations at IWH are a crucial part of the commercialization strategy, aiming to build awareness and confidence among the key opinion leaders and clinicians who drive market adoption. As healthcare systems seek solutions that not only improve patient outcomes but also deliver measurable value—by reducing hospital stays, antibiotic use, and the need for more invasive procedures—products with strong clinical evidence in tough-to-treat populations are poised for success.

“These presentations highlight Kane Biotech’s dedication to advancing wound care innovation across a spectrum of challenging conditions,” said Dr. Robert B. Huizinga, Interim CEO of Kane Biotech, in a recent statement. “By sharing our latest data at IWH, we continue to strengthen our role as a trusted partner in improving patient outcomes and supporting health systems with effective, science-driven solutions.”

As this technology moves further from the lab to the bedside, its versatility across different wound types, dressing protocols, and application frequencies is a key asset. For the millions of individuals living with the daily reality of a non-healing wound, innovations that directly address the root cause of persistence offer more than just a new treatment option; they offer a renewed possibility of closure.